NewLink Genetics (NLNK) Tops Q1 EPS by 88c
Get Alerts NLNK Hot Sheet
Join SI Premium – FREE
NewLink Genetics (NASDAQ: NLNK) reported Q1 EPS of ($0.82), $0.88 better than the analyst estimate of ($1.70). Revenue for the quarter came in at $4.34 million versus the consensus estimate of $2.08 million.
NewLink Genetics ended the quarter on March 31, 2016, with cash, cash equivalents, and certificates of deposit totaling $178 million compared to $197.8 million for the year ending December 31, 2015. The decrease was attributable primarily due to the increased operating expenses for R&D and pre-commercialization development, offset by amounts received under government contracts.
For earnings history and earnings-related data on NewLink Genetics (NLNK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gilead Sciences (GILD) Misses Q1 EPS by 288c
- ResMed (RMD) Tops Q3 EPS by 20c
- Skechers USA (SKX) Tops Q1 EPS by 23c, Beats on Revenue; Offers FY24 Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!